Central nervous system cancers, version 1.2015: Featured updates to the NCCN guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 13, Issue 10, 2015, Pages 1191-1202

  Nabors, Louis Burt ^a   Portnow, Jana ^b   Ammirati, Mario ^c   Baehring, Joachim ^d   Brem, Henry ^e   Brown, Paul ^f   Butowski, Nicholas ^g   Chamberlain, Marc C ^h   Fenstermaker, Robert A ⁱ   Friedman, Allan ^j   Gilbert, Mark R ^f   Hattangadi Gluth, Jona ^k   Holdhoff, Matthias ^e   Junck, Larry ^l   Kaley, Thomas ^m   Lawson, Ronald ⁿ   Loeffler, Jay S ^o   Lovely, Mary P ^p   Moots, Paul L ^q   Mrugala, Maciej M ^h   Newton, Herbert B ^c   Parney, Ian ^r   Raizer, Jeffrey J ^s   Recht, Lawrence ^t   Shonka, Nicole ^u   Shrieve, Dennis C ^v   Sills, Allen K ^q   Swinnen, Lode J ^e   Tran, David ^w   Tran, Nam ^x   Vrionis, Frank D ^x   Weiss, Stephanie ^y   Wen, Patrick Yung ^z   McMillian, Nicole ^aa   Engh, Anita M ^aa   more..

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Hope Comprehensive Cancer Center   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d YALE CANCER CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h SEATTLE CANCER CARE ALLIANCE   (United States)

ⁱ ROSWELL PARK CANCER INSTITUTE   (United States)

^j DUKE CANCER INSTITUTE   (United States)

^k UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^l UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^m MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁿ UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^o MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^p American Brain Tumor Association   (United States)

^q VANDERBILT INGRAM CANCER CENTER   (United States)

^r MAYO CLINIC CANCER CENTER   (United States)

^s NORTHWESTERN UNIVERSITY   (United States)

^t STANFORD CANCER INSTITUTE   (United States)

^u UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^v UNIVERSITY OF UTAH   (United States)

^w BARNES JEWISH HOSPITAL   (United States)

^x H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^y FOX CHASE CANCER CENTER   (United States)

^z Dana Farber Brigham and Women's Cancer Center   (United States)

^aa National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE;

CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; ELECTRIC FIELD THERAPY; ELECTROSTIMULATION THERAPY; GERIATRIC PATIENT; GLIOBLASTOMA; GLIOMA; HIGH RISK PATIENT; HUMAN; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL PERFORMANCE; PRACTICE GUIDELINE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ADULT; CENTRAL NERVOUS SYSTEM NEOPLASMS; METASTASIS; PATHOLOGY;

ADULT; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; NEOPLASM METASTASIS; PRACTICE GUIDELINES AS TOPIC;

EID: 84944744220     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2015.0148     Document Type: Review

References (74)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
2. Piepmeier J, Christopher S, Spencer D, et al. Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery 1996;38:872-878; discussion 878-879.
3. Afra D, Osztie E, Sipos L, Vitanovics D. Preoperative history and postoperative survival of supratentorial low-grade astrocytomas. Br J Neurosurg 1999;13:299-305.
4. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.
5. CBTRUS: Statistical report: Primary Brain Tumors in the United States, 1995- 1999. Chicago, IL: Central Brain Tumor Registry of the United States; 2002.
6. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002;20:2076-2084.
7. Daniels TB, Brown PD, Felten SJ, et al. Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys 2011;81:218-224.
8. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 1996;36:549-556.
9. Lo SS, Cho KH, Hall WA, et al. Does the extent of surgery have an impact on the survival of patients who receive postoperative radiation therapy for supratentorial low-grade gliomas? Int J Cancer 2001;96(Suppl):71-78.
10. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of lowversus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002;20:2267-2276.
11. Lo SS, Hall WA, Cho KH, et al. Radiation dose response for supratentorial low-grade glioma-institutional experience and literature review. J Neurol Sci 2003;214:43-48.
12. Jeremic B, Milicic B, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial low-grade glioma: a 10-year update of a phase II study. Int J Radiat Oncol Biol Phys 2003;57:465-471.
13. Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeondetermined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg 2008;109:835-841.
14. Nitta M, Muragaki Y, Maruyama T, et al. Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection. Neurosurg Focus 2015;38:E7.
15. Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010;75:1560-1566.
16. Philippon JH, Clemenceau SH, Fauchon FH, Foncin JF. Supratentorial lowgrade astrocytomas in adults. Neurosurgery 1993;32:554-559.
17. Kang HC, Kim IH, Eom KY, et al. The role of radiotherapy in the treatment of newly diagnosed supratentorial low-grade oligodendrogliomas: comparative analysis with immediate radiotherapy versus surgery alone. Cancer Res Treat 2009;41:132-137.
18. Kaya V, Aksu MG, Korcum AF, et al. Clinical prognostic factors of adjuvant radiation therapy for low-grade gliomas: results of 10 years survival. Int J Clin Exp Med 2014;7:1336-1343.
19. Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro Oncol 2009;11:437-445.
20. Turkoglu E, Gurer B, Sanli AM, et al. Clinical outcome of surgically treated low-grade gliomas: a retrospective analysis of a single institute. Clin Neurol Neurosurg 2013;115:2508-2513.
21. Shaw EG, Daumas-Duport C, Scheithauer BW, et al. Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg 1989;70:853-861.
22. Yeh SA, Lee TC, Chen HJ, et al. Treatment outcomes and prognostic factors of patients with supratentorial low-grade oligodendroglioma. Int J Radiat Oncol Biol Phys 2002;54:1405-1409.
23. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366:985-990.
24. Ruda R, Magliola U, Bertero L, et al. Seizure control following radiotherapy in patients with diffuse gliomas: a retrospective study. Neuro Oncol 2013;15:1739-1749.
25. Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol 2012;30:3065-3070.
26. Gorlia T, Wu W, Wang M, et al. New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. Neuro Oncol 2013;15:1568-1579.
27. Buglione M, Pedretti S, Gipponi S, et al. Radiotherapy in low-grade glioma adult patients: a retrospective survival and neurocognitive toxicity analysis. Radiol Med 2014;119:432-439.
28. Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol 2007;14:391-398.
29. Iwadate Y, Matsutani T, Hasegawa Y, et al. Favorable long-term outcome of lowgrade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy. J Neurooncol 2011;102:443-449.
30. Buckner JC, Gesme D, Jr., O'Fallon JR, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 2003;21:251-255.
31. Buckner JC, Pugh SL, Shaw EG, et al. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG [abstract]. J Clin Oncol 2014;32(Suppl):Abstract 2000.
32. Buckner J, Shaw E, Pugh S, et al. R9802: Phase III study of radiation therapy (RT) with or without procarbazine CCNU, and vincristine (PCV) in lowgrade glioma: results by histologic type [abstract AT-13]. Neuro-Oncology 2014;16:v11.
33. Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 2003;14:1715-1721.
34. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22:3133-3138.
35. Kesari S, Schiff D, Drappatz J, et al. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 2009;15:330-337.
36. Everhard S, Kaloshi G, Criniere E, et al. MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 2006;60:740-743.
37. Pouratian N, Gasco J, Sherman JH, et al. Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J Neurooncol 2007;82:281-288.
38. Sherman JH, Moldovan K, Yeoh HK, et al. Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. J Neurosurg 2011;114:1617-1621.
39. Baumert BG, Mason WP, Ryan G, et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: a randomized phase III intergroup study by the EORTC/NCIC-CTG/ TROG/MRC-CTU (EORTC 22033-26033) [abstract]. J Clin Oncol 2013;31(Suppl):Abstract 2007.
40. Fisher BJ, Hu C, Macdonald DR, et al. Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424. Int J Radiat Oncol Biol Phys 2015;91:497-504.
41. Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 2006;106:1759-1765.
42. Kaloshi G, Benouaich-Amiel A, Diakite F, et al. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 2007;68:1831-1836.
43. Tosoni A, Franceschi E, Ermani M, et al. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol 2008;89:179-185.
44. Peyre M, Cartalat-Carel S, Meyronet D, et al. Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol 2010;12:1078-1082.
45. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol 2014;16 Suppl 4:iv1-63.
46. Wachtel MS, Yang S. Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era. Cancer Med 2014;3:660-666.
47. Darefsky AS, King JT Jr, Dubrow R. Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries. Cancer 2012;118:2163-2172.
48. Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012;13:916-926.
49. Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983;52:997-1007.
50. Minniti G, Scaringi C, Lanzetta G, et al. Standard (60 gy) or short-course (40 gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis. Int J Radiat Oncol Biol Phys 2015;91:109-115.
51. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTCNCIC trial. Lancet Oncol 2009;10:459-466.
52. Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978;49:333-343.
53. Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47:649-652.
54. Andersen AP. Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radiol Oncol Radiat Phys Biol 1978;17:475-484.
55. Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007;356:1527-1535.
56. Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22:1583-1588.
57. Brandes AA, Vastola F, Basso U, et al. A prospective study on glioblastoma in the elderly. Cancer 2003;97:657-662.
58. Minniti G, De Sanctis V, Muni R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 2008;88:97-103.
59. Reddy K, Damek D, Gaspar LE, et al. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2012;84:655-660.
60. Iuchi T, Hatano K, Kodama T, et al. Phase 2 trial of hypofractionated highdose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 2014;88:793-800.
61. Ney DE, Carlson JA, Damek DM, et al. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. J Neurooncol 2015;122:135-143.
62. Miwa K, Matsuo M, Ogawa S, et al. Hypofractionated high-dose irradiation with positron emission tomography data for the treatment of glioblastoma multiforme. Biomed Res Int 2014;2014:407026.
63. Terasaki M, Eto T, Nakashima S, et al. A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme. J Neurooncol 2011;102:247-253.
64. Jastaniyah N, Murtha A, Pervez N, et al. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. Radiat Oncol 2013;8:38.
65. Yoon SM, Kim JH, Kim SJ, et al. Hypofractionated intensity-modulated radiotherapy using simultaneous integrated boost technique with concurrent and adjuvant temozolomide for glioblastoma. Tumori 2013;99:480-487.
66. Chen C, Damek D, Gaspar LE, et al. Phase I trial of hypofractionated intensitymodulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2011;81:1066-1074.
67. Panet-Raymond V, Souhami L, Roberge D, et al. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis. Int J Radiat Oncol Biol Phys 2009;73:473-478.
68. Minniti G, Lanzetta G, Scaringi C, et al. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys 2012;83:93-99.
69. Floyd SR, Kasper EM, Uhlmann EJ, et al. Hypofractionated Radiotherapy and Stereotactic Boost with Concurrent and Adjuvant Temozolamide for Glioblastoma in Good Performance Status Elderly Patients - Early Results of a Phase II Trial. Front Oncol 2012;2:122.
70. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 2012;48:2192-2202.
71. Mrugala MM, Engelhard HH, Dinh Tran D, et al. Clinical practice experience with NovoTTF-100A system for glioblastoma: The Patient Registry Dataset (PRiDe). Semin Oncol 2014;41 Suppl 6:S4-S13.
72. Stupp R, Taillibert S, Kanner A, et al. Tumor treating fields (TTFields): A novel treatment modality added to standard chemo- and radiotherapy in newly diagnosed glioblastoma-First report of the full dataset of the EF14 randomized phase III trial. ASCO Meeting Abstracts 2015;33:2000.
73. Stupp R, Wong E, Scott C, et al. NT-40Interim Analysis of the EF-14 Trial: A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM. Neuro-Oncology 2014;16:v167.
74. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA- 08 randomised, phase 3 trial. Lancet Oncol 2012;13:707-715.